Purpose: Early differentiation between transient congenital hypothyroidism (TCH) and permanent congenital hypothyroidism (PCH) is crucial for optimizing the duration of treatment. This retrospective cohort study aimed to evaluate whether levothyroxine (LT4) dose requirements over time can predict TCH and guide earlier discontinuation of treatment. Methods: We retrospectively analyzed 105 infants with congenital hypothyroidism and normal thyroid glands confirmed by imaging at a single tertiary care center (Inha University Hospital) between January 2013 and December 2022. Patients were classified into TCH (n=70) or PCH (n=35) based on thyroid function after LT4 withdrawal at 3 years of age. LT4 dose/kg at 6, 12, and 24 months, along with clinical and biochemical parameters, were compared between the 2 groups. Receiver operating characteristic (ROC) curve analysis was used to assess the predictive performance of LT4 dose thresholds. Results: The LT4 dose was significantly lower in the TCH group at 6 (3.16±0.83 μg/kg vs. 3.75±0.99 μg/kg, P=0.005), 12 (2.51±0.82 μg/kg vs. 3.37±1.17 μg/kg, P<0.001), and 24 months (2.02±0.61 μg/kg vs. 3.09±1.19 μg/kg, P<0.001). ROC curve analysis showed an area under the curve (AUC) of 0.649, 0.746, and 0.794 at 6, 12, and 24 months, respectively. A logistic regression model incorporating LT4 dose, birth weight, and thyroid-stimulating hormone (TSH) levels improved prediction accuracy (AUC: 0.740, 0.782, 0.833 at 6, 12, and 24 months, respectively). Conclusion LT4 dose requirements at 6, 12, and 24 months serve as useful indicators for differentiating TCH from PCH. A combined predictive model incorporating LT4 dose, birth weight, and TSH levels may improve diagnostic accuracy, supporting earlier discontinuation of treatment.

Purpose: Based on the KEYNOTE-522 study, neoadjuvant pembrolizumab plus chemotherapy has become the standard treatment for early-stage triple-negative breast cancer (TNBC).This study evaluated the real-world efficacy, safety, and predictors of pathologic complete response (pCR) in Korean patients. Methods: We conducted a retrospective cohort study of 174 patients with early-stage TNBC who received the KEYNOTE-522 regimen (neoadjuvant pembrolizumab plus paclitaxel and carboplatin, followed by doxorubicin and cyclophosphamide) at a tertiary cancer center between August 2022 and July 2024. We assessed the primary endpoints, including pCR rate and event-free survival (EFS). We performed univariable and multivariable logistic regression analyses to identify independent predictors of pCR. Results: The median patient age was 50 years (range, 24–74 years). The clinical stages were II and III in 79.3% and 20.1% of patients, respectively, and 10.9% had clinical N3 disease. The overall pCR rate was 62.1%, and the N3 subgroup had a pCR rate of 47.4%. On multivariable analysis, high baseline Ki-67 expression (≥ median, 75%) was significantly associated with pCR (odds ratio, 2.84; 95% confidence interval, 1.45 to 5.66; p = 0.002). At a median followup of 18.4 months, the 12-month EFS rate was 97.4%, with significantly superior outcomes observed in patients who achieved pCR compared with those who did not achieve pCR (100% vs. 93.1%, p = 0.007). The treatment completion rate was 92.0%, and immune-related adverse events occurred in 13.8% of patients. Conclusion In this real-world analysis of one of the largest Asian cohorts of patients with earlystage TNBC treated with neoadjuvant pembrolizumab, the KEYNOTE-522 regimen demonstrated substantial efficacy and manageable toxicity, consistent with the original trial findings.

Breast cancer is a complex disease influenced by environmental, genetic, dietary, and hormonal factors. This underscores the importance of postoperative nutritional management in supporting recovery, minimizing complications, and enhancing long-term outcomes. This review synthesizes clinical guidelines, expert recommendations, and observational studies to provide a comprehensive overview of dietary interventions for breast cancer patients following surgery. Post-surgical nutritional care is centered around three primary objectives: supporting wound healing through high-quality protein intake, maintaining optimal nutritional status to prevent malnutrition, and promoting healthy lifestyle habits to reduce the risk of recurrence. To achieve these objectives, postoperative dietary strategies focus on several key components: ensuring adequate hydration for metabolic processes and tissue repair, consuming a balanced diet rich in fresh vegetables and fruits to mitigate oxidative stress, incorporating whole grains to support overall healing, and maintaining sufficient intake of high-quality protein from sources such as fish, meat, and dairy products to aid tissue repair and immune system recovery. Patients are also advised to avoid alcohol, limit saturated fats, and reduce intake of salty, sugary, and smoked foods to minimize inflammation. As research progresses, the implementation of personalized dietary plans remains essential for optimizing recovery outcomes in breast cancer patients.

Breast cancer is a complex disease influenced by environmental, genetic, dietary, and hormonal factors. This underscores the importance of postoperative nutritional management in supporting recovery, minimizing complications, and enhancing long-term outcomes. This review synthesizes clinical guidelines, expert recommendations, and observational studies to provide a comprehensive overview of dietary interventions for breast cancer patients following surgery. Post-surgical nutritional care is centered around three primary objectives: supporting wound healing through high-quality protein intake, maintaining optimal nutritional status to prevent malnutrition, and promoting healthy lifestyle habits to reduce the risk of recurrence. To achieve these objectives, postoperative dietary strategies focus on several key components: ensuring adequate hydration for metabolic processes and tissue repair, consuming a balanced diet rich in fresh vegetables and fruits to mitigate oxidative stress, incorporating whole grains to support overall healing, and maintaining sufficient intake of high-quality protein from sources such as fish, meat, and dairy products to aid tissue repair and immune system recovery. Patients are also advised to avoid alcohol, limit saturated fats, and reduce intake of salty, sugary, and smoked foods to minimize inflammation. As research progresses, the implementation of personalized dietary plans remains essential for optimizing recovery outcomes in breast cancer patients.

Purpose: This study analyzed the pathological complete response (pCR) rates, long-term outcomes, and biological features of human epidermal growth factor receptor 2 (HER2)-zero, HER2-low, and HER2-positive breast cancer patients undergoing neoadjuvant treatment. Methods: This single-center study included 1,667 patients who underwent neoadjuvant chemotherapy from 2008 to 2014. Patients were categorized by HER2 status, and their clinicopathological characteristics, chemotherapy responses, and recurrence-free survival (RFS) rates were analyzed. Results: Patients with HER2-low tumors were more likely to be older (p = 0.081), have a lower histological grade (p < 0.001), and have hormone receptor (HorR)-positive tumors (p < 0.001). The HER2-positive group exhibited the highest pCR rate (23.3%), followed by the HER2-zero (15.5%) and HER2-low (10.9%) groups. However, the pCR rate did not differ between HER2-low and HER2-zero tumors in the HorR-positive or HorR-negative subgroups.The 5-year RFS rates increased in the following order: HER2-low, HER2-positive, and HER2-zero (80.0%, 77.5%, and 74.5%, respectively) (log-rank test p = 0.017). A significant survival difference between patients with HER2-low and HER2-zero tumors was only identified in HorR-negative tumors (5-year RFS for HER2-low, 74.5% vs. HER2-zero, 66.0%; log-rank test p-value = 0.04). Multivariate survival analysis revealed that achieving a pCR was the most significant factor associated with improved survival (hazard ratio [HR], 4.279; p < 0.001).Compared with HER2-zero, the HRs for HER2-low and HER2-positive tumors were 0.787 (p = 0.042) and 0.728 (p = 0.005), respectively. After excluding patients who received HER2-targeted therapy, patients with HER2-low tumors exhibited better RFS than those with HER2-zero (HR 0.784, p = 0.04), whereas those with HER2-positive tumors exhibited no significant difference compared with those with HER2-low tumors (HR, 0.975; p = 0.953). Conclusion Patients with HER2-low tumors had no significant difference in pCR rate compared to HER2-zero but showed better survival, especially in HorR-negative tumors.Further investigation into biological differences is warranted.

Purpose: This study analyzed the pathological complete response (pCR) rates, long-term outcomes, and biological features of human epidermal growth factor receptor 2 (HER2)-zero, HER2-low, and HER2-positive breast cancer patients undergoing neoadjuvant treatment. Methods: This single-center study included 1,667 patients who underwent neoadjuvant chemotherapy from 2008 to 2014. Patients were categorized by HER2 status, and their clinicopathological characteristics, chemotherapy responses, and recurrence-free survival (RFS) rates were analyzed. Results: Patients with HER2-low tumors were more likely to be older (p = 0.081), have a lower histological grade (p < 0.001), and have hormone receptor (HorR)-positive tumors (p < 0.001). The HER2-positive group exhibited the highest pCR rate (23.3%), followed by the HER2-zero (15.5%) and HER2-low (10.9%) groups. However, the pCR rate did not differ between HER2-low and HER2-zero tumors in the HorR-positive or HorR-negative subgroups.The 5-year RFS rates increased in the following order: HER2-low, HER2-positive, and HER2-zero (80.0%, 77.5%, and 74.5%, respectively) (log-rank test p = 0.017). A significant survival difference between patients with HER2-low and HER2-zero tumors was only identified in HorR-negative tumors (5-year RFS for HER2-low, 74.5% vs. HER2-zero, 66.0%; log-rank test p-value = 0.04). Multivariate survival analysis revealed that achieving a pCR was the most significant factor associated with improved survival (hazard ratio [HR], 4.279; p < 0.001).Compared with HER2-zero, the HRs for HER2-low and HER2-positive tumors were 0.787 (p = 0.042) and 0.728 (p = 0.005), respectively. After excluding patients who received HER2-targeted therapy, patients with HER2-low tumors exhibited better RFS than those with HER2-zero (HR 0.784, p = 0.04), whereas those with HER2-positive tumors exhibited no significant difference compared with those with HER2-low tumors (HR, 0.975; p = 0.953). Conclusion Patients with HER2-low tumors had no significant difference in pCR rate compared to HER2-zero but showed better survival, especially in HorR-negative tumors.Further investigation into biological differences is warranted.

Breast cancer is a complex disease influenced by environmental, genetic, dietary, and hormonal factors. This underscores the importance of postoperative nutritional management in supporting recovery, minimizing complications, and enhancing long-term outcomes. This review synthesizes clinical guidelines, expert recommendations, and observational studies to provide a comprehensive overview of dietary interventions for breast cancer patients following surgery. Post-surgical nutritional care is centered around three primary objectives: supporting wound healing through high-quality protein intake, maintaining optimal nutritional status to prevent malnutrition, and promoting healthy lifestyle habits to reduce the risk of recurrence. To achieve these objectives, postoperative dietary strategies focus on several key components: ensuring adequate hydration for metabolic processes and tissue repair, consuming a balanced diet rich in fresh vegetables and fruits to mitigate oxidative stress, incorporating whole grains to support overall healing, and maintaining sufficient intake of high-quality protein from sources such as fish, meat, and dairy products to aid tissue repair and immune system recovery. Patients are also advised to avoid alcohol, limit saturated fats, and reduce intake of salty, sugary, and smoked foods to minimize inflammation. As research progresses, the implementation of personalized dietary plans remains essential for optimizing recovery outcomes in breast cancer patients.

Breast cancer is a complex disease influenced by environmental, genetic, dietary, and hormonal factors. This underscores the importance of postoperative nutritional management in supporting recovery, minimizing complications, and enhancing long-term outcomes. This review synthesizes clinical guidelines, expert recommendations, and observational studies to provide a comprehensive overview of dietary interventions for breast cancer patients following surgery. Post-surgical nutritional care is centered around three primary objectives: supporting wound healing through high-quality protein intake, maintaining optimal nutritional status to prevent malnutrition, and promoting healthy lifestyle habits to reduce the risk of recurrence. To achieve these objectives, postoperative dietary strategies focus on several key components: ensuring adequate hydration for metabolic processes and tissue repair, consuming a balanced diet rich in fresh vegetables and fruits to mitigate oxidative stress, incorporating whole grains to support overall healing, and maintaining sufficient intake of high-quality protein from sources such as fish, meat, and dairy products to aid tissue repair and immune system recovery. Patients are also advised to avoid alcohol, limit saturated fats, and reduce intake of salty, sugary, and smoked foods to minimize inflammation. As research progresses, the implementation of personalized dietary plans remains essential for optimizing recovery outcomes in breast cancer patients.

Breast cancer is a complex disease influenced by environmental, genetic, dietary, and hormonal factors. This underscores the importance of postoperative nutritional management in supporting recovery, minimizing complications, and enhancing long-term outcomes. This review synthesizes clinical guidelines, expert recommendations, and observational studies to provide a comprehensive overview of dietary interventions for breast cancer patients following surgery. Post-surgical nutritional care is centered around three primary objectives: supporting wound healing through high-quality protein intake, maintaining optimal nutritional status to prevent malnutrition, and promoting healthy lifestyle habits to reduce the risk of recurrence. To achieve these objectives, postoperative dietary strategies focus on several key components: ensuring adequate hydration for metabolic processes and tissue repair, consuming a balanced diet rich in fresh vegetables and fruits to mitigate oxidative stress, incorporating whole grains to support overall healing, and maintaining sufficient intake of high-quality protein from sources such as fish, meat, and dairy products to aid tissue repair and immune system recovery. Patients are also advised to avoid alcohol, limit saturated fats, and reduce intake of salty, sugary, and smoked foods to minimize inflammation. As research progresses, the implementation of personalized dietary plans remains essential for optimizing recovery outcomes in breast cancer patients.

Purpose: This study analyzed the pathological complete response (pCR) rates, long-term outcomes, and biological features of human epidermal growth factor receptor 2 (HER2)-zero, HER2-low, and HER2-positive breast cancer patients undergoing neoadjuvant treatment. Methods: This single-center study included 1,667 patients who underwent neoadjuvant chemotherapy from 2008 to 2014. Patients were categorized by HER2 status, and their clinicopathological characteristics, chemotherapy responses, and recurrence-free survival (RFS) rates were analyzed. Results: Patients with HER2-low tumors were more likely to be older (p = 0.081), have a lower histological grade (p < 0.001), and have hormone receptor (HorR)-positive tumors (p < 0.001). The HER2-positive group exhibited the highest pCR rate (23.3%), followed by the HER2-zero (15.5%) and HER2-low (10.9%) groups. However, the pCR rate did not differ between HER2-low and HER2-zero tumors in the HorR-positive or HorR-negative subgroups.The 5-year RFS rates increased in the following order: HER2-low, HER2-positive, and HER2-zero (80.0%, 77.5%, and 74.5%, respectively) (log-rank test p = 0.017). A significant survival difference between patients with HER2-low and HER2-zero tumors was only identified in HorR-negative tumors (5-year RFS for HER2-low, 74.5% vs. HER2-zero, 66.0%; log-rank test p-value = 0.04). Multivariate survival analysis revealed that achieving a pCR was the most significant factor associated with improved survival (hazard ratio [HR], 4.279; p < 0.001).Compared with HER2-zero, the HRs for HER2-low and HER2-positive tumors were 0.787 (p = 0.042) and 0.728 (p = 0.005), respectively. After excluding patients who received HER2-targeted therapy, patients with HER2-low tumors exhibited better RFS than those with HER2-zero (HR 0.784, p = 0.04), whereas those with HER2-positive tumors exhibited no significant difference compared with those with HER2-low tumors (HR, 0.975; p = 0.953). Conclusion Patients with HER2-low tumors had no significant difference in pCR rate compared to HER2-zero but showed better survival, especially in HorR-negative tumors.Further investigation into biological differences is warranted.